WilmerHale Counsels Catabasis in $42M Public Offering

Download IconDownload Print IconPrint

WilmerHale Counsels Catabasis in $42M Public Offering

Firm News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the closing of a $42 million underwritten public offering of common stock and warrant units on June 22, 2018. Oppenheimer & Co. Inc. is acting as the sole underwriter for the offering. Catabasis intends to use the net proceeds for the planned Phase 3 clinical trial of edasalonexent for the treatment of Duchenne muscular dystrophy, as well as for working capital and other corporate purposes.

The WilmerHale team representing Catabasis is led by Rosemary Reilly and includes Jeffries Oliver-Li and Libby Ragan.

Read Catabasis’ press release about the offering. 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel